2026-06-10T01:19:21Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/116202026-05-15T06:32:10Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

00925njm 22002777a 4500 dc Pérez Gómez, Noelia author Martínez-Zamora, María Ángeles author Carmona, Francisco author Novalbos, Jesús author Abad-Santos, Francisco author Koller, Dora author Saiz Rodríguez, Miriam author 2026-03 Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. It affects approximately 10–15% of women of reproductive age globally and is characterized by heterogeneous symptoms with chronic pelvic pain, dysmenorrhea, and infertility being the most common. Although pharmacological treatments are available to manage its symptoms, many women either do not respond to these therapies or experience adverse drug reactions (ADRs) that outweigh the original symptoms of endometriosis. Current research highlights a critical gap in pharmacogenetic biomarkers for endometriosis treatment, limiting the potential for personalized therapeutic strategies. Integrative multi-omics approaches combining genetic, inflammatory, and hormonal profiles may enhance patient stratification and optimize individualized care. 0724-8741 https://hdl.handle.net/10259/11620 10.1007/s11095-026-04049-9 1573-904X Drug response Endometriosis Pharmacogenetics Precision medicine An Overview of Endometriosis and Potential Pharmacogenetic Targets